Precision BioSciences (DTIL) Q1 2026 earnings review
Runway Secured, Execution Mode Engaged
Precision BioSciences delivered a textbook quarter for a clinical-stage biotech: they contained costs, advanced their lead clinical assets, and banked a key partner milestone. Revenue was $10.8M, driven primarily by a $7.5M payment from TG Therapeutics, while strict operational discipline pushed Total Operating Expenses down to $19.9M. The most critical takeaway for investors is the Stable cash runway. With $125.8M in the bank, management extended its funding guidance through 2028. This completely removes the near-term financing overhang and ensures the company is fully funded to deliver critical Phase 1/2 clinical readouts for both its Hepatitis B and Duchenne Muscular Dystrophy programs.
🐂 Bull Case
Extending the cash runway through 2028 is a massive de-risking event. It allows management to focus entirely on clinical execution rather than highly dilutive capital raises in a tough macro environment.
The $7.5M milestone from TG Therapeutics and upcoming ASGCT data from partner iECURE prove that the ARCUS gene-editing platform has commercial and clinical viability beyond the wholly-owned pipeline.
🐻 Bear Case
While the cash balance looks healthy at $125.8M, it came at a severe cost. Basic outstanding shares have exploded by 165% year-over-year, heavily capping per-share upside for long-term holders.
The company relies entirely on lumpy, unpredictable milestone payments. Base operations remain deeply unprofitable, and there is no recurring revenue floor.
⚖️ Verdict: ⚪
Cautiously Optimistic. The clinical progress is on track and the balance sheet is secure through 2028. However, the extreme historical dilution and reliance on lumpy partner milestones require investors to have high conviction in the upcoming clinical readouts to justify an entry here.
Key Themes
PBGENE-HBV Nears Critical Data Expansion
Accelerating. Precision's lead Hepatitis B program, PBGENE-HBV, is advancing smoothly through its dose-escalation cohorts. The ARCUS technology specifically targets the elimination of cccDNA—the root cause of viral replication. This is a massive product innovation that differentiates it from traditional therapies that only suppress the virus. Management expects to share further clinical data at the EASL Congress in May 2026, setting the stage for the crucial expansion phase of the ELIMINATE-B trial.
PBGENE-DMD Crosses the Clinical Starting Line
Accelerating. The PBGENE-DMD program transitioned from preclinical to clinical reality this quarter. Following FDA IND clearance and Fast Track designation in Q1, Precision activated its first site at Arkansas Children's Hospital. The gene excision approach aims to restore functional dystrophin protein, targeting up to 60% of Duchenne patients. Dosing the first patient is the next major inflection point.
Aggressive Cost Control Defends the Balance Sheet
Decelerating. Management has successfully tamed operating costs. General and Administrative (G&A) expenses fell 20% year-over-year to $6.8M, reflecting strict operational discipline and lower headcount costs. Research & Development (R&D) also edged lower to $13.1M. This Decelerating expense profile is the primary reason the company was able to extend its cash runway through 2028.
The True Cost of Cash: Severe Dilution
Accelerating. The positive narrative of a $125.8M cash fortress is directly contradicted by the dilution required to build it. Weighted-average basic shares outstanding surged from 9.3 million in 25Q1 to 24.6 million in 26Q1—a 165% increase. While necessary to survive the macro environment for biotech funding, this structural ceiling limits the EPS impact of future clinical successes.
Revenue Remains Entirely Event-Driven
Stable. Total revenue of $10.8M looks great compared to the near-zero revenue in Q1 of last year. However, this is not structural growth. It was entirely driven by a $7.5M milestone from TG Therapeutics and a legacy agriculture agreement. Without a recurring revenue base, the top line will remain extremely volatile.
Non-Cash Accounting Noise Masks Bottom Line
Reversing. The company reported a net loss of $18.4M, but this includes a massive $9.4M in total other expenses. This was primarily driven by a $7.1M non-cash loss on the change in fair value of warrant liabilities. Investors must strip out this noise to see the true cash burn, but the accounting volatility makes headline EPS a poor metric for judging the company's health.
Other KPIs
Stable. Down slightly from $137.2 million at the end of 2025, but robust enough to secure operations through 2028. The cash burn of roughly $11.3M for the quarter was heavily subsidized by the $7.5M TG Therapeutics milestone payment.
Decelerating. Down from $22.1 million in 25Q1. Management successfully reduced G&A by $1.8M while keeping R&D flat, even as PBGENE-DMD transitioned into an active clinical trial phase.
Guidance
Accelerating. Upgraded from previous guidance of 'into the second half of 2027'. This ensures the company can fully fund PBGENE-HBV and PBGENE-DMD through their critical Phase 1/2 data readouts without needing immediate dilutive financing.
Accelerating. A late-breaking poster presentation is confirmed for the EASL Congress, focusing on the first evidence of cccDNA elimination in liver biopsies. This is the ultimate proof-of-concept event for the ARCUS platform.
Stable. iECURE expects to present OTC-HOPE trial data at ASGCT in May 2026, and TG Therapeutics plans to present preliminary Phase 1 data for Azer-Cel in progressive multiple sclerosis in the second half of 2026.
Key Questions
Clinical Trial Burn Rates
With PBGENE-DMD entering the FUNCTION-DMD clinical trial and activating sites, how should we model the sequential increase in R&D expenses for the remainder of 2026?
Future Milestone Visibility
The Q1 cash burn was heavily offset by the TG Therapeutics milestone. Are there any other near-term partner milestones modeled into your 'cash runway through 2028' guidance?
Warrant Liability Dynamics
Can you provide more color on the mechanics driving the $7.1 million loss on warrant liabilities this quarter, and how sensitive this line item is to future share price fluctuations?